Tuesday 2nd December – Day 2 Main Conference - GMT (Greenwich Mean Time, GMTZ)
- Klara Kulenkampff - Implementation Lead, Process Engineering & Technology, Bayer
- Ian Rees - Assessor, MHRA
- Santiago Recuenco - Manager, Deloitte AG
- Karin Hoogendoorn - Head Drug Product Development (CART, Oncology), Galapagos BV
- Guido Moll - Assistant Coordinator EU-H2020 ATMP & GMP Projects, Charité, Universitätsmedizin Berlin
- Ian Rees - Assessor, MHRA
- Henriette Rozema - Head of Global Manufacturing Science and Technology, Galapagos
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator Berlin, Bayer
While the 20th century was the century of the discovery of the DNA structure (Watson and Crick, Nobel Prize 1962) and of the birth of the modern human genetics field, the 21st century is- and should properly be- the century of applying this knowledge on genes and genetics in treating fastidious human diseases. New fields such as gene and cell therapies are thus slowly emerging out of the womb of human genetics— from CRISPR and CRISPR therapeutics to various gene therapies. In this Keynote talk, we will describe recent advances in genetic engineering of disease models and of new therapies, as well as the challenges to be overcome in the future. We will outline the future milestones for the gene therapy field.
- Abraam Yakoub - Lead Investigator, Brigham and Women’s Hospital
- Ángel Lucio Pereira - Chief Executive Officer, Tetraneuron
- Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
- Tamás Kitka - Founder, Managing Director, CREATe Therapeutics
- Lucas Arruda - Chief Scientific Officer, CuraCell
- Dmitry Kalupin - CEO, Unlock Biology
- Christopher Bravery, Ph.D. - Consulting Regulatory Scientist, Advbiols
- Wenshi Wang - SVP Tech & Ops, FosunKairos
- Gonzalo Fernández-Miranda - CEO and Co-Founder, CureAge Therapeutics
- Lior Shaltiel - CEO, NurExone Biologic
- Round Table 1: AI Revolution in CGT Manufacturing – Beyond the Hype: Where is it Having an Impact?
Leader: Guido Moll, Assistant Coordinator EU-H2020 ATMP & GMP Projects, Charité, Universitätsmedizin Berlin
- Round Table 2: From Rare Diseases to Mainstream Markets: Unlocking CGT's Potential for Major Disease Indications
Leader: Hiroyuki Usuda, Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
- Guido Moll - Assistant Coordinator EU-H2020 ATMP & GMP Projects, Charité, Universitätsmedizin Berlin
- Hiroyuki Usuda - Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
- Wenshi Wang - SVP Tech & Ops, FosunKairos
- Jonas Båtelson - CEO, Curacell
- Bernd Muehlenweg - SVP, Head of Global Business Development, Cell Therapy - Global BD iPSC Cell Therapy, Evotec
- Ulrich Ruemenapp - Senior Biotech Program Lead, Bayer AG
- Matias Olsen - Senior Manager, Public Affairs and Policy, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
